These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31092464)

  • 21. [Clinical outcome of receptor expression discordance between primary and metastatic breast cancer].
    Mu YX; Zhang P; Ma F; Yuan P; Wang JY; Xu BH; Li Q
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):506-511. PubMed ID: 30060358
    [No Abstract]   [Full Text] [Related]  

  • 22. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    Schrijver WAME; Suijkerbuijk KPM; van Gils CH; van der Wall E; Moelans CB; van Diest PJ
    J Natl Cancer Inst; 2018 Jun; 110(6):568-580. PubMed ID: 29315431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
    Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
    Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraocular Metastases Secondary to Breast Carcinoma Correlates With Upregulation of Estrogen and Progesterone Receptor Expression in the Primary Tumor.
    Parrozzani R; Frizziero L; Testi I; Miglionico G; Perrini P; Pulze S; Pilotto E; Midena E
    Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):3944-8. PubMed ID: 27479811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.
    Walter V; Fischer C; Deutsch TM; Ersing C; Nees J; Schütz F; Fremd C; Grischke EM; Sinn P; Brucker SY; Schneeweiss A; Hartkopf AD; Wallwiener M
    Breast Cancer Res Treat; 2020 Aug; 183(1):137-144. PubMed ID: 32613540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormone receptor, human epidermal growth factor receptor-2, and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases.
    Yamanouchi K; Kuba S; Eguchi S
    Surg Today; 2020 Jul; 50(7):657-663. PubMed ID: 31190183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
    Chen J; Wu X; Christos PJ; Formenti S; Nagar H
    Breast Cancer Res; 2018 Apr; 20(1):26. PubMed ID: 29661221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
    Tas F
    Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 expression is a strong independent predictor of nodal metastasis in breast cancer.
    Ahmed AR
    J Egypt Natl Canc Inst; 2016 Dec; 28(4):219-227. PubMed ID: 27756653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis.
    Jung J; Lee SH; Park M; Youn JH; Shin SH; Gwak HS; Yoo H
    J Neurooncol; 2018 Apr; 137(2):295-302. PubMed ID: 29260362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
    Chapman JA; Sgroi DC; Goss PE; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Badovinac-Crnjevic T; Shepherd LE; Pollak MN
    Breast Cancer Res Treat; 2016 May; 157(1):101-8. PubMed ID: 27116182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
    Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
    Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of Expression of Breast Biomarkers in Primary and Metastatic Breast Carcinomas: A Single-Institution Experience.
    Hou Y; Shen R; Chaudhary S; Gao F; Li Z
    Acta Cytol; 2016; 60(5):481-489. PubMed ID: 27681712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discordance in receptor status between primary and metastatic breast cancer and overall survival: A single-center analysis.
    Mellouli M; Graja S; Kridis WB; Ayed HB; Makni S; Triki M; Charfi S; Khanfir A; Boudawara TS; Kallel R
    Ann Diagn Pathol; 2022 Dec; 61():152044. PubMed ID: 36099874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
    van Mackelenbergh MT; Denkert C; Nekljudova V; Karn T; Schem C; Marmé F; Stickeler E; Jackisch C; Hanusch C; Huober J; Fasching PA; Blohmer JU; Kümmel S; Müller V; Schneeweiss A; Untch M; von Minckwitz G; Weber KE; Loibl S
    Breast Cancer Res Treat; 2018 Jan; 167(1):59-71. PubMed ID: 28875243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.
    Jensen JD; Knoop A; Ewertz M; Laenkholm AV
    Breast Cancer Res Treat; 2012 Apr; 132(2):511-21. PubMed ID: 21667123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.